Additionally, FOXM1, HSP105α, ROBO1, and SPARC were identified as promising therapeutic targets in CRC, while FOXM1 and SPARC were excluded in liver metastases owing to their significantly reduced expression level. This evidence concerns the gene FOXM1 and colorectal carcinoma.